STOCK TITAN

Treace Medical Concepts Inc - TMCI STOCK NEWS

Welcome to our dedicated news page for Treace Medical Concepts (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Treace Medical Concepts's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Treace Medical Concepts's position in the market.

Rhea-AI Summary
Treace Medical Concepts, Inc. sponsors the first National Bunion Day in the U.S. and celebrates treating 100,000 patients with its Lapiplasty® 3D Bunion Correction® System. The company also launches a new patient education campaign.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Summary
Treace Medical Concepts, Inc. reported strong financial results for Q4 2023 and full-year 2023, with revenue increasing by 25% and 32% respectively. The company's gross margin remained robust at 81.6% in Q4 2023. Treace also saw a significant increase in active surgeons and direct sales representatives. The company's patent portfolio expanded, and it initiated commercialization of new technologies. Despite a net loss, Treace provided optimistic guidance for 2024, expecting revenue growth of 18-20% and improved Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
earnings
-
Rhea-AI Summary
Treace Medical Concepts, Inc. will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. The company will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. A live and archived webcast of the event and investor presentation will be available on the Company’s investor relations website. Treace routinely posts important information for investors in the 'Investor Relations' section of its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
conferences earnings
Rhea-AI Summary
Treace Medical Concepts, Inc. announces positive three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions. The study demonstrated consistent, positive radiographic and patient-reported outcomes maintained at three years, early return to weight bearing, low radiographic recurrence rates, reduction in pain, and significant improvement in patient-reported quality of life measures. Interim data from the Company’s Mini3D™ prospective, multicenter study also showed favorable clinical and patient-reported outcomes with a mini-incision approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
clinical trial
-
Rhea-AI Summary
Treace Medical Concepts, Inc. announces the full commercial release of its Micro-Lapiplasty™ System and limited clinical release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company will highlight new technology innovations and three-year interim ALIGN3D™ clinical results at the 2024 American College of Foot and Ankle Surgeons Annual Scientific Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
none
-
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time. Preliminary unaudited fourth quarter and full-year 2023 revenue results show a significant increase, with revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022, and revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increase of 32% at the midpoint compared to the prior year. Blended average revenue per Lapiplasty® procedure kit sold in the fourth quarter of 2023 was approximately $6,437, a record high and 9% increase over the same period in 2022. The company also saw substantial new active surgeon additions and a 35% increase in direct quota carrying sales representatives over year-end 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
none
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 3:45 pm Pacific Time. The CEO will discuss the company's flagship Lapiplasty® and Adductoplasty® Procedures. The webcast and replay will be available on the investor relations website. Treace routinely posts important information for investors on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
conferences
-
Rhea-AI Summary
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) reported a 23% increase in revenue to $40.8 million for the third quarter of 2023. The company also achieved a 36% year-to-date increase in revenue. The gross margin was 80.4% in the third quarter, and 81.0% year to date. Treace has expanded its patent portfolio to 52 granted U.S. patents, with additional patents worldwide and pending U.S. patent applications. The CEO, John T. Treace, highlighted a 21% increase in the surgeon base and a record blended average selling price of $6,311.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.9%
Tags
earnings
-
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on November 14, 2023. The CEO and CFO will discuss the Lapiplasty® 3D Bunion Correction® Procedure. A live webcast and replay will be available on the investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
Rhea-AI Summary
Treace Medical Concepts, Inc. will present new interim data for the ALIGN3D™ clinical study at the AOFAS Annual Meeting. The data shows early return to weight bearing in 8.4 days, low recurrence rate, and 81% reduction in pain. The company also highlights new product innovations, including the SpeedPlate™ and Micro-Lapiplasty™ technologies. Full commercial launch of these technologies is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
clinical trial
Treace Medical Concepts Inc

Nasdaq:TMCI

TMCI Rankings

TMCI Stock Data

763.29M
44.22M
29.02%
67.76%
4.86%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Ponte Vedra

About TMCI

treace medical concepts, inc. is a privately-funded, commercial stage company focused on bringing breakthrough technologies to the high-growth $1.1 billion us market for foot and ankle surgical products. we are committed to operating our business with the highest standards of ethical conduct. we will exceed our customers’ expectations through an innovation-driven, high-velocity approach to solving treatment and surgical problems. with our products and services, our mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for our employees and an exceptional return for our shareholders.